Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05451771 · ClinicalTrials.gov registry record · Phase 1
Venetoclax-Dexamethasone in Relapsed and/or Refractory t(11;14) Amyloidosis
A Phase 1 study of AL Amyloidosis, sponsored by Rajshekhar Chakraborty, MD.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 53
- Enrollment target
- 4
- Study locations
NCT05451771 is a Phase 1 study of AL Amyloidosis that is actively recruiting participants, run by Rajshekhar Chakraborty, MD. The registered enrollment target is 53 participants, below the 421-participant average among 15 other AL Amyloidosis trials with a reported enrollment target (87% lower). The trial reports 4 study locations across 4 states.
The verdict
NCT05451771, a Phase 1 study of AL Amyloidosis, is actively recruiting participants, sponsored by Rajshekhar Chakraborty, MD.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 53 participants
- Enrollment target
- 4
- Study locations
Study Summary
The purpose of this study is assess safety, safest dose, and effectiveness of venetoclax in combination with dexamethasone in participants with t(11;14) positive relapsed (comes back) or refractory (did not get better) light chain amyloidosis.
Conditions Studied
Interventions
- DRUG Venetoclax Oral Tablet, 200 mg
- DEVICE FISH assay
- DRUG Venetoclax Oral Tablet, 400 mg
- DRUG Dexamethasone Oral, 10 mg
- DRUG Dexamethasone Oral, 20 mg
Study Locations (4)
Massachusetts
- Boston Medical Center - Boston
Minnesota
- Mayo Clinic Rochester - Rochester
New York
- New York Presbyterian Hospital/Columbia University Irving Medical Center - New York
Wisconsin
- Froedtert Hospital & the Medical College of Wisconsin - Milwaukee
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 53 participants |
| Start Date | 2022-10-26 |
| Est. Completion | 2026-09 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05451771
The ClinicalTrials.gov registry entry for NCT05451771 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 53 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 421-participant average among 15 other AL Amyloidosis trials with a reported enrollment target (87% lower). The listed sponsor is Rajshekhar Chakraborty, MD, which has 2 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with AL Amyloidosis appearing as the primary indexed condition, and to 5 interventions - of which Venetoclax Oral Tablet, 200 mg is the first listed.
NCT05451771 reports 4 study locations spanning 4 distinct geographic areas - top geographies include Massachusetts, Minnesota, New York.
Frequently Asked Questions
What is clinical trial NCT05451771 about?
NCT05451771 is a clinical study titled "Venetoclax-Dexamethasone in Relapsed and/or Refractory t(11;14) Amyloidosis". The purpose of this study is assess safety, safest dose, and effectiveness of venetoclax in combination with dexamethasone in participants with t(11;14) positive relapsed (comes back) or refractory (did not get better) light chain amyloidosis.
What is the current status of trial NCT05451771?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 53 participants. The study started on 2022-10-26. Estimated completion is 2026-09.
What conditions does trial NCT05451771 study?
This clinical trial studies the following conditions: AL Amyloidosis.
What interventions are being tested in trial NCT05451771?
The interventions under investigation include: Venetoclax Oral Tablet, 200 mg (DRUG), FISH assay (DEVICE), Venetoclax Oral Tablet, 400 mg (DRUG), Dexamethasone Oral, 10 mg (DRUG), Dexamethasone Oral, 20 mg (DRUG).
Who is sponsoring clinical trial NCT05451771?
This trial is sponsored by Rajshekhar Chakraborty, MD, which has 2 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05451771 being conducted?
This trial has 4 study locations across Massachusetts, Minnesota, New York, Wisconsin. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for AL Amyloidosis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Phase 1/2a Study of Belantamab Mafodotin in Relapsed or Refractory AL Amyloidosis
RECRUITING · Phase 1
-
Elranatamab in Patients With Relapsed or Refractory AL Amyloidosis
RECRUITING · Phase 1
-
Isatuximab as Upfront Therapy for the Treatment of High Risk AL Amyloidosis
ACTIVE NOT RECRUITING · Phase 1
-
Radioimmunoimaging of AL Amyloidosis
COMPLETED · Phase 1
-
Ohio State University Multiple Myeloma and Amyloidosis Data Registry and Sample Resource
RECRUITING
-
Comparing Dara-VCD Chemotherapy Plus Stem Cell Transplant to Dara-VCD Chemotherapy Alone for People Who Have Newly Diagnosed AL Amyloidosis
RECRUITING · Phase 3
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.